- Home
- HRTX
as 11-21-2024 12:36pm EST
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 180.5M | IPO Year: | 1987 |
| Target Price: | $5.67 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $3.93 | Next Earning Date: | 11-12-2024 |
| Revenue: | $137,737,000 | Revenue Growth: | 12.13% |
| Revenue Growth (this year): | 19.15% | Revenue Growth (next year): | 21.29% |
Latest Heron Therapeutics Inc. News
HRTX Breaking Stock News: Dive into HRTX Ticker-Specific Updates for Smart Investing
GuruFocus.com
8 days ago
Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive ...
Zacks
9 days ago
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks
9 days ago
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Associated Press Finance
9 days ago
Heron Therapeutics: Q3 Earnings Snapshot
PR Newswire
9 days ago
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
Zacks
14 days ago
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics
Simply Wall St.
16 days ago
Positive Signs As Multiple Insiders Buy Heron Therapeutics Stock
PR Newswire
17 days ago
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
Compare HRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HRTX Heron Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.